Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Institute of Psoriasis, School of Medicine, Tongji University, Shanghai 200443, China.
Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Institute of Psoriasis, School of Medicine, Tongji University, Shanghai 200443, China.
Clin Immunol. 2024 Feb;259:109899. doi: 10.1016/j.clim.2024.109899. Epub 2024 Jan 5.
Generalized pustular psoriasis (GPP) is a severe and uncommon form of psoriasis, for which treatment options are limited. There is an urgent need to expand the treatment options for GPP. Currently, adalimumab, secukinumab, and guselkumab are considered effective for GPP, but there is a lack of prospective direct comparative studies on their efficacy for GPP. We conducted a prospective, single-center, observational study on 50 GPP patients to compare the efficacy, safety, and recurrence rates of these three biologics. Adalimumab, secukinumab, and guselkumab resulted in varying degrees of improvement in patients with GPP, but guselkumab exhibited superior efficacy and a lower recurrence rate than the other two drugs. This enhanced response may be attributed to the significant reduction in CD8+ tissue-resident memory T cells within GPP lesions caused by guselkumab.
泛发性脓疱型银屑病（GPP）是一种严重且不常见的银屑病形式，其治疗选择有限。因此，迫切需要扩大 GPP 的治疗选择。目前，阿达木单抗、司库奇尤单抗和古塞库单抗被认为对 GPP 有效，但缺乏对这三种生物制剂治疗 GPP 的疗效的前瞻性直接比较研究。我们对 50 例 GPP 患者进行了一项前瞻性、单中心、观察性研究，以比较这三种生物制剂的疗效、安全性和复发率。阿达木单抗、司库奇尤单抗和古塞库单抗使 GPP 患者的病情得到不同程度的改善，但古塞库单抗的疗效优于其他两种药物，复发率也较低。这种增强的反应可能归因于古塞库单抗导致 GPP 病变中 CD8+组织驻留记忆 T 细胞的显著减少。
